587
Views
52
CrossRef citations to date
0
Altmetric
Research Article

Nosocomial imipenem-resistant Acinetobacter baumannii infections: Epidemiology and risk factors

, , &
Pages 741-746 | Received 08 Feb 2010, Accepted 19 Apr 2010, Published online: 26 May 2010

References

  • Hanlon GW. The emergence of multidrug resistant Acinetobacter species: a major concern in the hospital setting. Lett Appl Microbiol 2005;41:375–8.
  • Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008;46:1254–63.
  • Baran G, Erbay A, Bodur H, Onguru P, Akinci E, Balaban N, . Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis 2008;12:16–21.
  • Cisneros JM, Rodriguez-Bano J, Fernandez-Cuenca F, Ribera A, Vila J, Pascual A, . Spanish Group for Nosocomial Infection (GEIH) for the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC): Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study. Clin Microbiol Infect 2005;11:874–9.
  • Lee SO, Kim NJ, Choi SH, Hyong Kim T, Chung JW, Woo JH, . Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 2004;48:224–8.
  • Playford EG, Craig JC, Iredell JR. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect 2007;65:204–11.
  • Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988;16:128–40.
  • Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infection, 1992: a modification of CDC definition of surgical wound infections. Infect Control Hosp Epidemiol 1992;13:606–8.
  • Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 15th Informational supplement. M100-S15. Wayne, PA: CLSI; 2005.
  • Rodriguez-Bano J, Cisneros JM, Fernandez-Cuenca F, Ribera A, Vila J, Pascual A, . Grupo de Estudio de Infección Hospitalaria (GEIH): Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol 2004;25: 819–24.
  • Apisarnthanarak A, Pinitchai U, Thongphubeth K, Yuekyen C, Warren DK, Fraser VJ. A multifaceted intervention to reduce pandrug-resistant Acinetobacter baumannii colonization and infection in 3 intensive care units in a Thai tertiary care center: a 3-year study. Clin Infect Dis 2008;47:760–7.
  • Turner PJ, Greenhalgh JM. The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997–2000. Clin Microbiol Infect 2003;9:563–7.
  • Gales AC, Jones RN, Forward KR, Liñares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). Clin Infect Dis 2001;32(Suppl 2):104–13.
  • Yucesoy M, Yulug N, Kocagoz S, Unal S, Cetin S, Calangu S. Antimicrobial resistance of Gram-negative isolates from intensive care units in Turkey: comparison to previous three years. J Chemother 2000;12:294–8.
  • Aksaray S, Dokuzoguz B, Guvener E, Yucesoy M, Yulug N, Kocagoz S, . Surveillance of antimicrobial resistance among Gram-negative isolates from intensive care units in eight hospitals in Turkey. J Antimicrob Chemother 2000; 45:695–9.
  • Korten V, Ulusoy S, Zarakolu P, Mete B. Turkish MYSTIC Study Group: Antibiotic resistance surveillance over a 4-year period (2000–2003) in Turkey: results of the MYSTIC Program. Diagn Microbiol Infect Dis 2007;59:453–7.
  • del Mar Tomas M, Cartelle M, Pertega S, Beceiro A, Llinares P, Canle D, . Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect 2005;11:540–6.
  • Ferrara AM. Potentially multidrug-resistant non-fermentative Gram-negative pathogens causing nosocomial pneumonia. Int J Antimicrob Agents 2006;27:183–95.
  • Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, Aldabó-Pallás T. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Int Care Med 2005;31:649–55.
  • Clark NM, Patterson J, Lynch PJ III. Antimicrobial resistance among Gram-negative organisms in the intensive care unit. Curr Opin Crit Care 2003;9:413–23.
  • Chastre J. Infections due to Acinetobacter baumannii in the ICU. Semin Respir Crit Care Med 2003;24:69–78.
  • Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 2000;30:454–60.
  • Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents 2008;32: 29–32.
  • Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005;52: 203–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.